The role of Telmisartan in osteoblastic differentiation in spontaneously hypertensive rats

• Grant number: 17/02271-2
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: May 01, 2017
• End date: March 31, 2019
• Field of knowledge: Health Sciences - Dentistry
• Principal Investigator: Sandra Helena Penha de Oliveira
• Grantee: Mariana Sousa Patrocinio
• Host Institution: Faculdade de Odontologia (FOA). Universidade Estadual Paulista (UNESP). Campus de Araçatuba. Araçatuba , SP, Brazil
• Associated research grant: 15/03965-2 - Role of the renin-angiotensin system in different oral inflammatory models: an experimental interdisciplinary and clinical approach, AP.TEM

Abstract

Suppression of the renin-angiotensin system (RAS) for decades is desired for the treatment of systemic arterial hypertension, due to its effects of vasoconstriction and increased blood pressure. Currently, various drugs are capable of performing such study, for example, telmisartan which is an angiotensin II (AT 1) type 1 receptor antagonist. The RAS also operates locally and its components are expressed in different tissues, such as bone. Previous studies have shown that angiotensin II (AngII) can enhance bone resorption by increasing RANKL expression, inducing osteoclast activation, and has effects on osteocalcin, causing changes in osteoblastic maturation. Thus, attention has been focused to the role of RAS in the development of osteometabolic pathologies, such as osteoporosis, which presents a higher prevalence in hypertensive individuals. Telmisartan is not only AT1 antagonist but also exerts an agonist function under the PPAR-³ receptors, these receptors contribute to bone loss by suppressing osteoblastic differentiation and induce adipogenic differentiation. Based on these indications, we will evaluate the role of telmisartan in osteoblastic differentiation in spontaneously hypertensive animal (SHR) mesenchymal stem cell (SHR) culture using cell proliferation rate, total protein content, alkaline phosphatase activity, biological mineralization and adipogenic differentiation assays . (AU)

Scientific publications

(The scientific publications listed on this page originate from the Web of Science or SciELO databases. Their authors have cited FAPESP grant or fellowship project numbers awarded to Principal Investigators or Fellowship Recipients, whether or not they are among the authors. This information is collected automatically and retrieved directly from those bibliometric databases.)

BALERA BRITO, VICTOR GUSTAVO; PATROCINIO, MARIANA SOUSA; LINJARDI SOUSA, MARIA CAROLINA; ALVES BARRETO, AYNA EMANUELLI; TFAILE FRASNELLI, SABRINA CRUZ; LARA, VANESSA SOARES; SANTOS, CARLOS FERREIRA; PENHA OLIVEIRA, SANDRA HELENA. Mast cells contribute to alveolar bone loss in Spontaneously Hypertensive Rats with periodontal disease regulating cytokines production. PLoS One, v. 16, n. 3, MAR 4 2021. (18/23676-3, 17/05873-3, 17/07095-8, 17/02271-2, 15/03965-2)

BRITO, VICTOR GUSTAVO BALERA; PATROCINIO, MARIANA SOUSA; BARRETO, AYNA EMANUELLI ALVES; FRASNELLI, SABRINA CRUZ TFAILE; LARA, VANESSA SOARES; SANTOS, CARLOS FERREIRA; OLIVEIRA, SANDRA HELENA PENHA. Telmisartan impairs the in vitro osteogenic differentiation of mesenchymal stromal cells from spontaneously hypertensive male rats. European Journal of Pharmacology, v. 912, DEC 5 2021. (17/02271-2, 15/03965-2, 17/05873-3, 18/23676-3)

BRITO, VICTOR GUSTAVO BALERA; PATROCINIO, MARIANA SOUSA; DE SOUSA, MARIA CAROLINA LINJARDI; BARRETO, AYNA EMANUELLI ALVES; FRASNELLI, SABRINA CRUZ TFAILE; LARA, VANESSA SOARES; SANTOS, CARLOS FERREIRA; OLIVEIRA, SANDRA HELENA PENHA. Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease. FRONTIERS IN PHARMACOLOGY, v. 11, NOV 11 2020. (17/02271-2, 18/23676-3, 17/05873-3, 17/07095-8, 15/03965-2)